Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2021-02, Vol.100 (2), p.595-599
Hauptverfasser:	Shahswar, Rabia, Beutel, Gernot, Gabdoulline, Razif, Koenecke, Christian, Markel, Dominik, Eder, Matthias, Stadler, Michael, Gohring, Gudrun, Schlegelberger, Brigitte, Trummer, Arne, Krauter, Juergen, Thol, Felicitas, Heuser, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Azacitidine - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - adverse effects Cytarabine - therapeutic use Decitabine - therapeutic use Female Hematology Humans Letter to the Editor Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - physiopathology Male Medicine Medicine & Public Health Middle Aged Oncology Risk Factors Sulfonamides - administration & dosage Sulfonamides - adverse effects Tumor Lysis Syndrome - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!